pharmaceuticals

pharmaceuticals Articles

Shares of Aeri Pharmaceuticals skyrocketed early Thursday after the company issued positive results on its intraocular pressure (IOP) treatment in patients with glaucoma.
Agios Pharmaceuticals has filed with the SEC regarding a secondary offering of up to $150 million of its common stock.
The goal of Allergan’s bid for Vitae Pharmaceuticals is to bolster its dermatology product pipeline, and Vitae shareholders appear happy to oblige.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
If we look at what Horizon is paying, it doesn’t necessarily add up, using the numbers from this year, but if we look at more data the picture becomes clearer.
Some biotech companies made impressive runs over the course of this past week. These select few stood out from the rest.
Lexicon Pharmaceuticals rallied Friday on late-stage results from a pivotal Phase 3 clinical trial of a type 1 diabetes treatment.
24/7 Wall St. has been concerned about the longer-term implications of GW Pharma over other emerging drug and biotech outfits.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
One election year hot-button issue that is back on the table is the ongoing fight over drug prices. But the public has been debating drug prices for years now — long before the EpiPen price hike...
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.